TRAF2 Protein Capture of HCV p21 Capsid for Early Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for Hepatitis C virus (HCV) are inadequate due to delayed detection, high costs, and the need for specialized equipment and expertise, leading to challenges in early and sensitive detection, especially in resource-limited settings.
Innovation Solution
The use of Factor 2 protein associated with the tumor necrosis factor receptor (TRAF2) or its homologs to capture and detect the viral capsid protein p21 of HCV, forming a protein complex that enhances detection sensitivity at low concentrations, allowing for early, rapid, and cost-effective diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-based detection methods are used for HCV, then detection sensitivity is improved, but detection time is delayed (30-45 days required for seroconversion)
Solution Approach 1:
The patent introduces TRAF2 protein as an intermediary capture agent that binds directly to the HCV p21 capsid protein. This mediator enables direct detection of the viral protein itself rather than waiting for antibody production, thereby resolving the contradiction between detection sensitivity and detection time by creating a direct protein-protein interaction pathway that bypasses the seroconversion delay.
2Measurement precision
If RNA detection methods are used for HCV, then detection sensitivity is improved, but device complexity and cost increase due to specialized equipment requirements
Solution Approach 1:
The patent employs TRAF2 protein as a disposable capture agent that can be immobilized on simple solid supports. This approach replaces complex, expensive RNA detection equipment with simple, inexpensive protein-based capture systems that can be implemented using basic laboratory equipment, thereby resolving the contradiction between detection sensitivity and device complexity.
3Measurement precision
If automated detection systems are used for HCV, then detection precision is improved, but ease of operation deteriorates due to requirement for specialized expertise
Solution Approach 1:
The patent designs a detection system where TRAF2 protein automatically captures the HCV p21 capsid protein through specific protein-protein interactions. This self-service mechanism eliminates the need for complex automated systems and specialized expertise, as the biological recognition event occurs spontaneously, thereby resolving the contradiction between detection precision and ease of operation.
4Reliability
If multiple viral components are detected for HCV diagnosis, then reliability is improved, but device complexity and cost increase
Solution Approach 1:
The patent demonstrates that TRAF2 protein can universally capture different HCV genotypes through its binding to the conserved p21 capsid protein structure. This multi-functional capability allows a single detection system to reliably detect diverse HCV strains, thereby resolving the contradiction between diagnostic reliability and device complexity by achieving broad coverage through one capture agent rather than multiple component-specific tests.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables reliable, sensitive, and inexpensive detection of HCV infection, potentially reducing false negatives and improving early diagnosis, making it suitable for resource-limited settings and enhancing public health outcomes.
Implementation Method 1
the TRAF2 protein can bind a viral HCV capsid protein, or p21, and form with it, through direct protein-protein interactions, a protein complex
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention concerns the in vitro or ex vivo use of at least one factor 2 protein associated with the receptor of the tumour necrosis factor, TRAF2, or of a homolog of TRAF2, as an agent for detecting a viral capsid protein of the Hepatitis C virus, p21, or of a homolog of same.